SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

$SWEAT is the beating heart of the Movement Economy—a groundbreaking token that transforms physical activity into real-world value. Minted through movement, $SWEAT rewards your steps with a crypto asset that you can earn, trade, or grow. The team states that their app has increased their users’ physical activity by an average of 20%, creating a healthier society and reducing burdens on global healthcare systems. With over 20 million holders, SWEAT is eliminating barriers and making Web3 accessible to everyone, one step at a time.

Sweat Economy

Sweat Economy is seeing renewed community interest with many users discussing its potential for a long-term turnaround while others actively track its price movements and trading volume. Discussions frequently center around the project's longevity, comparisons to historical market patterns, and a vocal base of long-term holders hopeful for a significant recovery.

Amentum Holdings, Inc. engages in mission-critical, technology-driven services in government and commercial markets. It operates through the Digital Solutions and Global Engineering Solutions segments. The Digital Solutions segment provides advanced digital and data-driven solutions including intelligence analytics, space system development, cybersecurity, and next generation IT. The Global Engineering Solutions segment manages large-scale environmental remediation, nuclear power solutions, platform engineering, sustainment and supply chain management. The company was founded on November 26, 2019 and is headquartered in Chantilly, VA.

Amentum Holdings Inc.

Amentum Holdings is experiencing significant volatility and downward pressure as investors navigate a broader defense sector sell-off and frustration over the stock's failure to maintain intraday gains. Despite these headwinds, the community remains divided, with many long-term shareholders highlighting the company's robust $47 billion backlog and critical government contracts in space and nuclear energy as reasons to hold for a potential reversal.

Ideal Power, Inc. engages in the development of power converter solutions for photovoltaic generation, grid-storage and electrified vehicle charging. Its products include solar inverters, bi-directional battery, electric vehicle chargers, photovoltaic inverters and battery converters. It is focused on its patented Bidirectional, Bipolar Junction Transistor (B-TRAN) semiconductor technology. The company was founded by William C. Alexander on May 17, 2007 and is headquartered in Austin, TX.

Ideal Power Inc

Ideal Power is gaining significant momentum as the community monitors its early completion of the first B-TRAN design win, which delivered a substantial reduction in power losses compared to traditional technology. Investors are closely tracking the company's progress with high-profile automotive partnerships, specifically Stellantis, as the community discusses the potential for these collaborations to serve as catalysts for future commercial scaling and profitability.

Amphenol Corp. engages in the design, manufacture, and marketing of electrical, electronic and fiber optic connectors, interconnect systems, antennas, sensors and sensor-based products, and specialty cable. It operates through the following segments: Harsh Environment Solutions, Communications Solutions, and Interconnect and Sensor Systems. The Harsh Environment Solutions segment manufactures and markets a broad range of ruggedized interconnect products, including connectors and interconnect systems, printed circuits and printed circuit assemblies, and other products. The Communications Solutions segment focuses on the design, manufacture, and marketing of connector and interconnect systems, including radio frequency, power, fiber optic, and other products, together with antennas. The Interconnect and Sensor Systems segment is involved in the design, manufacture, and marketing of sensors, sensor-based systems, connectors, and value-add interconnect systems. The company was founded by Schmitt J. Arthur in 1932 and is headquartered in Wallingford, CT.

Amphenol Corp. - Ordinary Shares - Class A

Amphenol is trending as investors weigh its robust growth in AI-driven data center infrastructure against concerns over its premium valuation and persistent insider selling. The community remains divided, with many bullish on its long-term potential as a diversified blue-chip compounder, while others are wary of recent price volatility and bond offerings.

Ethereum is a global, open-source platform for decentralized applications. In other words, it is a decentralized blockchain platform that enables developers to build and deploy smart contracts and applications without central authority control. Unlike Bitcoin, which primarily functions as digital currency, Ethereum operates as a programmable global computer where developers can create any type of decentralized service.   The platform hosts over $14 billion in DeFi applications with hundreds of thousands of active users across financial protocols, NFT marketplaces, and gaming platforms. Its transition to Proof of Stake in September 2022 reduced energy consumption by over 99%, addressing environmental concerns while strengthening network security.  The network operates through thousands of independent validator nodes that process transactions and execute smart contracts on the Ethereum Virtual Machine. Smart contracts are self-executing programs written in Solidity that automatically carry out agreements when conditions are met, eliminating intermediaries like banks or brokers.   Validators stake ETH as collateral to propose and validate blocks, earning rewards for honest participation while facing penalties for malicious behavior. The EIP-1559 upgrade introduced a dynamic base fee mechanism that burns ETH with each transaction, creating deflationary pressure during high network activity when more ETH is burned than issued to validators.  Vitalik Buterin proposed Ethereum in 2013, but seven co-founders helped build it, including Gavin Wood who created Solidity and the EVM technical specification, and Joseph Lubin who founded ConsenSys. The project launched in July 2015 after raising over $18 million through crowdfunding, quickly becoming the largest blockchain developer community. Major milestones include the 2020 Beacon Chain launch, the 2021 London hard fork implementing fee burning, and the 2022 Merge to Proof of Stake.   Ether (ETH) serves multiple functions: paying transaction fees (gas), staking to secure the network and earn 3-5% annual yields, serving as collateral in DeFi protocols, and purchasing NFTs and digital assets. The asset is increasingly adopted by traditional institutions, with publicly traded companies adding ETH to corporate treasuries to generate staking yields while maintaining blockchain exposure, and in 2024, the SEC approved spot Ethereum ETFs, allowing traditional investors to gain exposure through conventional brokerage accounts.  Ethereum's roadmap focuses on dramatically increasing transaction capacity to over 100,000 per second, reducing confirmation times, and enhancing decentralization while maintaining security against future threats like quantum computing.

Ethereum

Ethereum is facing intense volatility and bearish sentiment as traders track the upcoming Senate Banking Committee markup of the Clarity Act, which many hope will provide necessary regulatory legitimacy. While some community members are bracing for further downside or labeling the asset a laggard, others are focused on institutional developments like JPM's tokenized money-market fund as proof that core infrastructure adoption is quietly accelerating.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is experiencing heightened volatility and intense community debate as market participants weigh recent institutional buying activity against shifting sentiment regarding legislative progress and inflationary pressures. While some investors view the current price fluctuations as a strategic consolidation ahead of long-term growth, others remain cautious, highlighting the asset's sensitivity to broader macroeconomic trends and liquidations in leveraged positions.

Bitmine Immersion Technologies, Inc. is a technology company focused on acquiring, holding, and actively managing ETH as its primary treasury reserve asset. It prioritizes digital ecosystem services, such as consultancy and advisory works. The company was founded on August 16, 1995 and is headquartered in Las Vegas, NV.

BitMine Immersion Technologies Inc

Bitmine Immersion Technologies Inc

Bitmine Immersion Technologies (BMNR) is facing intense community skepticism and volatility as investors weigh the company's decision to slow Ethereum accumulation against the upcoming Senate committee vote on the Clarity Act. While bulls point to the potential for institutional adoption and long-term upside in tokenization, retail sentiment remains sharply divided, with critics voicing significant frustration over the stock's recent underperformance relative to other crypto-linked equities.

XRP is a decentralized digital asset and the native token of the XRP Ledger, a Layer 1 blockchain designed for high-performance global payments. Its primary value proposition is offering a fast, cost-effective alternative to traditional banking systems by enabling near-instant cross-border settlements that finalize in three to five seconds. By serving as a neutral bridge asset between different fiat currencies, it helps financial institutions lower liquidity costs and eliminates the need for pre-funded accounts.  The network is unique because it utilizes a federated consensus protocol instead of energy-intensive mining or staking. This system achieves deterministic finality through a Unique Node List of trusted validators who must reach an eighty percent agreement threshold to permanently record transactions. This infrastructure supports a sustained throughput of 1,500 transactions per second and includes a built-in decentralized exchange that allows for the automated trading of any tokenized asset without intermediaries.  The project traces its origins back to 2004 with Ryan Fugger before being co-founded in its modern form by Jed McCaleb and Chris Larsen. The company, now known as Ripple, works with major financial institutions as partners and investors to build global payment solutions. To protect the network from spam, a small amount of XRP is burned during every transaction, and the token is further utilized by institutions as collateral to access traditional markets and manage digital asset infrastructure.  Institutional adoption of the asset reached a major milestone in November 2025 when the SEC approved the first wave of spot XRP ETFs. These products, offered by major issuers including Bitwise, Grayscale, 21Shares, Canary Capital, and Franklin Templeton, are now listed on prominent exchanges like the NYSE Arca, Nasdaq, and Cboe BZX. While Ripple remains a key contributor to the ecosystem, the underlying XRP Ledger continues to operate as an open-source and decentralized network.

Ripple

The community is closely watching the Senate Banking Committee's markup session on the CLARITY Act, with many investors speculating on how the proposed regulatory framework could impact long-term institutional adoption and asset classification. While some traders are expressing optimism over potential legal clarity and bullish price momentum, others remain skeptical, warning of persistent volatility and continued skepticism regarding the coin's ability to maintain gains.

Evolution Metals & Technologies Corp. engages in developing a global supply chain for critical minerals and materials. It focuses on automotive, renewable energy, and military and defense sectors. The company is headquartered in West Palm Beach, FL.

Evolution Metals & Technologies Corp.

Evolution Metals & Technologies Corp. Common Stock

Evolution Metals & Technologies Corp. (EMAT) is gaining significant community attention as a low-float play, fueled by investor excitement over its vertically integrated rare earth magnet operations and recent strategic partnerships. Traders are actively tracking the stock's volatility and supply chain narrative, viewing it as a potential candidate for rapid price appreciation while monitoring its recent Nasdaq debut.

Altria Group, Inc. is a holding company, which engages in the manufacture and sale of cigarettes in the United States. It operates through the following segments: Smokeable Products, Oral Tobacco Products, and All Other. The Smokeable Products segment consists of cigarettes manufactured and sold by PM USA, and machine-made large cigars and pipe tobacco manufactured and sold by Middleton. The Oral Tobacco Products segment includes MST and snus products manufactured and sold by USSTC, and oral nicotine pouches manufactured and sold by Helix. The All Other segment refers to the financial results of NJOY, Helix ROW, and the IQOS System heated tobacco business. The company was founded in 1919 and is headquartered in Richmond, VA.

Altria Group Inc.

Altria Group ($MO) is trending as investors rotate into defensive, high-yield dividend stocks amid broader market volatility and uncertainty. The community is actively discussing the stock's stability and reliability as a 'safe haven' investment, while continuing to focus on its long-term pricing power and dividend growth track record.

statis crypto Watchlist

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>REGENXBIO, however, noted that the U.S. Food and Drug Administration recommended a randomized controlled trial for the drug in recent discussions, raising cash concerns.</li><li>Cash, cash equivalents, and marketable securities stood at $150.5 million at Q1-end, which the firm expects to be sufficient to fund its operations into early 2027.</li><li>Both Q1 revenue and earnings fell short of Wall Street expectations on Thursday.</li></ul>Shares of REGENXBIO Inc. (RGNX) dropped 37% on Thursday after the company reported disappointing first-quarter 2026 (Q1) financial results that overshadowed positive pivotal late-stage trial data for its lead Duchenne muscular dystrophy candidate RGX-202.The stock is on track for its worst day ever, if losses hold.<h2 class="st-heading-2">RGNX’s Q1 Earnings</h2>The company reported that revenue for the three months ended March 31 plunged to $6.4 million from $89.0 million a year earlier, and below an analyst estimate of $25.25 million. The steep decline was driven by the absence of a $70 million upfront license payment recognized in Q1 2025 under the Nippon Shinyaku collaboration and lower royalties from Novartis’ ZOLGENSMA after U.S. patent expiration in January 2026.REGENXBIO swung to a net loss of $90.1 million, or $1.72 per share, compared with net income of $6.1 million, or $0.12 per share, in the prior-year quarter. Wall Street, on average, had estimated a loss of only $1.3/ share.Cash, cash equivalents, and marketable securities stood at $150.5 million at quarter-end, which the firm expects to be sufficient to fund its operations into early 2027.<h2 class="st-heading-2">DMD Trial Readout</h2>In a separate announcement, REGENXBIO reported strong results from its main late-stage trial of RGX-202 for Duchenne muscular dystrophy. Duchenne muscular dystrophy (DMD) is a severe, progressive genetic disorder characterized by muscle degeneration and weakness, primarily affecting young boys.The study met its main goal. Ninety-three percent of patients produced high levels of the needed muscle protein after 12 weeks, averaging 71%.One-year data from some patients showed meaningful improvements in movement and muscle function compared to untreated boys. The treatment was generally safe, with two serious side effects that resolved, Regenxbio said.The results support plans for an accelerated approval filing and subsequent launch in 2027, the firm said. REGENXBIO, however, noted that the U.S. Food and Drug Administration recommended a randomized controlled trial for the drug in recent discussions, which could add uncertainty to the timeline, though the company remains optimistic and plans further FDA discussions.<h2 class="st-heading-2"> How Did RGNX Retail Traders React?</h2>On Stocktwits, retail sentiment around RGNX stock increased from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume increased from ‘high’ to ‘extremely high’ levels.A Stocktwits user expressed hopes for the stock recovering after the “overreaction.” The user sees the company’s market cap touching $1 billion in time, up from its current near $330 million market cap now.<stembedurl>https://www.stocktwits.com/buymoremakemore/message/653352403</stembedurl>Another user expressed hopes for Novartis buying the company.<stembedurl>https://www.stocktwits.com/murphylaw/message/653377645</stembedurl>Another user highlighted that the company doesn’t seem to have enough cash to conduct another trial if the FDA insists.<stembedurl>https://www.stocktwits.com/Find_the_Cure/message/653359896</stembedurl><a href="https://stocktwits.com/symbol/RGNX">RGNX stock</a> has fallen by about 23% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/ivvd-stock-fell-today-but-this-analyst-sees-730-percent-upside/cZX1UFNReSa">IVVD Stock Tanks 19% Today – But This Analyst Believes It Has A Potential Upside Of Over 730%</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Regenxbio logo is displayed on the screen of a smart tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

RGNX Stock On Track For Worst Day Ever As Big Q1 Loss, Cash Concerns Eclipse Duchenne Trial Success  

REGENXBIO on Thursday reported strong results from its main late-stage trial of RGX-202 for Duchenne muscular dystrophy.

Equity

REGENXBIO on Thursday reported strong results from its main late-stage trial of RGX-202 for Duchenne muscular dystrophy.


REGENXBIO Advances Duchenne Gene Therapy Toward Accelerated Approval

REGENXBIO reports positive Phase 3 Duchenne trial data as RGX-202 met its primary endpoint with strong safety results.read more...

Regenxbio Shares Rise After Positive Duchenne Trial Results

Regenxbio Shares Rise After Positive Duchenne Trial Results...

Regenxbio (RGNX) Reports Q1 Loss, Lags Revenue Estimates

Regenxbio (RGNX) delivered earnings and revenue surprises of -26.94% and -73.13%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

REGENXBIO Reports First Quarter 2026 Financial Results and Operational Highlights

REGENXBIO Reports First Quarter 2026 Financial Results and Operational Highlights REGENXBIO Reports First Quarter 2026 Financial Results and Operational Highlights PR Newswire ROCKVILLE, Md., May 14...

REGENXBIO Announces Positive Topline Results from Pivotal Phase III AFFINITY DUCHENNE Study of RGX-202

REGENXBIO Announces Positive Topline Results from Pivotal Phase III AFFINITY DUCHENNE Study of RGX-202 REGENXBIO Announces Positive Topline Results from Pivotal Phase III AFFINITY DUCHENNE Study of...

<ul class="summary-bullets"><li>The plans come on the heels of several complaints from the pharmaceutical industry and sparring with others in the health department over policy, the report added.</li><li>Makary, a former Johns Hopkins surgeon, joined the FDA in November 2024.</li><li>Shares of REPL and QURE jumped as much 17% following the report.</li></ul>President Donald Trump is reportedly considering firing U.S. Food and Drug Administration Commissioner Marty Makary.The Wall Street Journal <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.wsj.com/health/healthcare/trump-planning-to-fire-fda-commissioner-marty-makary-34c072e2">reported</a> on the plans on Friday, citing people familiar with the matter, while noting that other top administration officials believe Makary is struggling to manage his agency. The plans come on the heels of several complaints from the pharmaceutical industry and sparring with others in the health department over policy, the report added.However, the president’s plans are not final and could change, the report said. WSJ noted that Makary, if fired, would become the latest top lieutenant to be fired under Health and Human Services Secretary Robert F. Kennedy Jr., following the departures of CDC Director Susan Monarez last summer and HHS Deputy Secretary Jim O’Neill in February.Makary, a former Johns Hopkins surgeon, joined the FDA in November 2024.<h2 class="st-heading-2">Companies Likely To Benefit from Makary’s Exit</h2>Several biotech and pharmaceutical firms that have publicly clashed with the Makary-led FDA over what they describe as inconsistent, unpredictable, or overly restrictive drug-review processes are viewed as potential beneficiaries of new leadership that could accelerate approvals and restore clearer regulatory guidance.Replimune Group Inc. (<a href="https://stocktwits.com/symbol/REPL">REPL</a>): The FDA rejected the company’s lead melanoma therapy RP1 in a high-profile decision that drew intense industry backlash. Replimune argued the agency treated it unfairly and failed to honor prior commitments made during review meetings; the case became a flashpoint in broader criticism of Makary’s tenure.uniQure N.V. (<a href="https://stocktwits.com/symbol/QURE">QURE</a>): The agency issued a sudden “key shift” in feedback on the company’s Huntington’s disease gene therapy AMT-130, reversing earlier assurances about the sufficiency of its Phase 1/2 data. The FDA strongly recommended a new, randomized, double-blind, sham-surgery-controlled trial.Moderna Inc. (<a href="https://stocktwits.com/symbol/MRNA">MRNA</a>): CEO Stéphane Bancel publicly stated that the FDA under Makary had become “unpredictable” in a way that “threatens U.S. leadership in innovative medicines.” The company experienced surprise setbacks, including an initial refusal to accept a flu vaccine application that was later reversed.Regenxbio Inc. (<a href="https://stocktwits.com/symbol/RGNX">RGNX</a>): The FDA declined to approve the company’s gene therapy for the ultra-rare Hunter syndrome (MPS II) in February 2026, despite prior engagement. Industry observers cited this as part of a pattern of moving goalposts that has frustrated rare-disease developers.Sarepta Therapeutics Inc. (<a href="https://stocktwits.com/symbol/SRPT">SRPT</a>): Sarepta faced repeated conflicts over its Duchenne muscular dystrophy gene therapy Elevidys, including safety and efficacy disputes under Makary’s oversight and the influence of former FDA official Vinay Prasad.Other biotech stocks likely to benefit from under new FDA leadership include Hims &amp; Hers Health (<a href="https://stocktwits.com/symbol/HIMS">HIMS</a>), which faced direct public criticism from Makary over its compounded GLP-1 weight-loss products, and rare-disease gene- and RNA-therapy developers such as Dyne Therapeutics (<a href="https://stocktwits.com/symbol/DYN">DYN</a>), Avidity Biosciences (<a href="https://stocktwits.com/symbol/RNA">RNA</a>), and Lexeo Therapeutics (<a href="https://stocktwits.com/symbol/LXEO">LXEO</a>), all of which have cited inconsistent feedback and delays during Makary’s tenure.Shares of REPL jumped 17% at the time of writing, while QURE rose 15%. MRNA traded 10% higher, while SRPT stock traded 3% lower, and RGNX shares stayed flat.<h2 class="st-heading-2">How Did Retail Traders React?</h2>A Stocktwits user voiced optimism for eventual approval of Replimune’s RP-1 drug, calling the decision to deny it approval a “terrible one.”<stembedurl>https://www.stocktwits.com/History101/message/652782029</stembedurl>Another voiced optimism for “someone better” replacing Makary.<stembedurl>https://www.stocktwits.com/blueb22/message/652773597</stembedurl>While REPL shares fell by about 50% over the past 12 months, QURE rose 124%.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/lucid-uber-partnership-accelerates-after-nuro-lands-key-california-permit-for-gravity-robotaxis/cZX2AwwReg1">LCID-UBER Partnership Accelerates After Nuro Lands Key California Permit for Gravity Robotaxis</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

FDA Commissioner Marty Makary speaks at a news conference on removing synthetic dyes from America's food supply, at the Health and Human Services Headquarters in Washington, DC on April 22, 2025. (Photo by Nathan Posner/Anadolu via Getty Images)

REPL, QURE, MRNA Soar On Reports Trump Will Fire FDA’s Marty Makary 

The Wall Street Journal reported on the plans on Friday, citing people familiar with the matter, while noting that other top administration officials believe Makary is struggling to manage his agency.

REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 2026 Annual Meeting

REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 2026 Annual Meeting REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 2026 Annual...

EyePoint (EYPT) Reports Q1 Loss, Tops Revenue Estimates

EyePoint (EYPT) delivered earnings and revenue surprises of -25.32% and +132.00%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

REGENXBIO to Host Webcast on May 14 to Discuss Topline Results from Pivotal Trial of RGX-202 for Duchenne Muscular Dystrophy

REGENXBIO to Host Webcast on May 14 to Discuss Topline Results from Pivotal Trial of RGX-202 for Duchenne Muscular Dystrophy REGENXBIO to Host Webcast on May 14 to Discuss Topline Results from...

$RGNX Q1 &#39;26 Earnings Results &amp; Recap

• Reported GAAP EPS of -$1.72 down -1533.33% YoY
• Reported revenue of $6.39M down -92.82% YoY
• Regenxbio expects its balance in cash, cash equivalents, and marketable securities of $150.5M as of March 31, 2026, to fund its operations into early 2027.

Stocktwits

 Q1 '26 Earnings Results & Recap

• Reported GAAP EPS of -$1.72 down -1533.33% YoY
• Reported revenue of $6.39M down -92.82% YoY
• Regenxbio expects its balance in cash, cash equivalents, and marketable securities of $150.5M as of March 31, 2026, to fund its operations into early 2027.

This account has been verified as an official STOCKTWITS representative.

Verified Account

Stocktwits Earnings

REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.

RGNX
Regenxbio Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Compact View

Earnings Recap

Latest RGNX News

RGNXRegenxbio Inc